Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. - Wikidata - awgldk - TriplyDB

Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.

Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q33265315

about

PGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.Elevated microRNA-135a is associated with pulmonary arterial hypertension in experimental mouse model.A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension.New perspectives for the treatment of pulmonary hypertension Pulmonary arterial hypertension: advances in pathophysiology and management.Pathogenic mechanisms of pulmonary arterial hypertension.The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.Molecular pathogenesis of pulmonary arterial hypertension Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs?Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension.Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.Cellular and molecular basis of pulmonary arterial hypertension.Gene therapy for pulmonary hypertension: prospects and challenges.Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH.From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension.The transforming growth factor-β-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease.Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension Genetics and the molecular pathogenesis of pulmonary arterial hypertension.Targeted delivery of genes to endothelial cells and cell- and gene-based therapy in pulmonary vascular diseases.BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling.BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.Acquired Mitochondrial Abnormalities, Including Epigenetic Inhibition of Superoxide Dismutase 2, in Pulmonary Hypertension and Cancer: Therapeutic Implications.Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.Genetics of pulmonary arterial hypertension: do the molecular findings have translational value?Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension.[The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?]

P2860

Q28578858-4BEBB994-D7FB-4F69-8EC4-00979F4E6314 Q33784417-96349378-E13D-49D5-8997-639DD6474362 Q33824233-61A8B70B-AF58-41C6-B832-C9D516AB400C Q33829248-4C3660A7-8600-4EA6-91AA-C3DB1FF6A54B Q33843949-D54D8E70-FCC5-4DDA-97E4-3FDFB2B7FFFB Q33849207-97B3EAF0-13D4-4811-B27A-52951EE3D956 Q34180746-F31BF4E0-776A-4650-8BCE-A4F9F0526CC9 Q34903204-CFA48628-8F43-41F5-B8DD-7DDDC5E57381 Q35732584-71B2809A-F848-4AA8-AD2B-D234D9AC033C Q36447388-56541C9F-5F57-4B26-8077-A8C9AA6A2612 Q36457064-231FBDD1-8124-4665-B97D-A5A794497620 Q36701812-3494A7B6-DE48-46BD-A285-5B658AAC8D3C Q36736065-7E926E4A-55C4-4E36-89B4-E7BBD0D13C51 Q36784800-786F337D-ED98-4A8A-B906-C60C4756435D Q36818791-017A2761-B091-4E42-9A93-83684B5CA770 Q37359377-34F9881F-3224-41DC-9EC6-6D7D045A3D2C Q37465320-3EE6B9A5-DC8B-4FCD-8554-B6432A40C857 Q37827155-4BEC1F51-8C58-47A8-A797-59AFD29CD399 Q37898745-E8B80AAB-204F-4932-9D79-30F5B8EF9319 Q37901411-725AC00D-E3D7-4F27-9E89-38897D51A763 Q38104321-D32CD5DD-A55D-46B8-B819-EFFA6D64B0A3 Q38105550-C80275DB-CCB9-4EDD-8C22-50C925FF9896 Q38146987-C8B25ED9-1116-4234-B886-82CD4459DFD1 Q38165146-973D960D-AE8E-47BD-8E6D-63465A10E6DA Q38799538-F4D6C055-6EB4-4065-B42B-E7CFD9424723 Q38817806-72E9A747-8272-405E-AC5A-B60EA12F3155 Q38876540-5FF904C5-6ADB-4DFF-8E47-60E6D8A2B199 Q40649909-2D4C93D8-6D1D-4F6D-BD19-F7C9ADF3D46D Q40776830-96B255D5-0563-47A1-886F-5BC7D6E5106F Q41838568-6E282265-1E52-4773-BBDF-E7A119B5A5B3 Q42173250-E0DA0E8C-E128-4065-8F6D-93C626853D02 Q52312423-6D7F5731-9986-48A8-BA88-8A97B38FC36D

P2860

Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q33265315

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Overexpression of human bone m ...... lmonary arterial hypertension.

@ast

Overexpression of human bone m ...... lmonary arterial hypertension.

@en

Overexpression of human bone m ...... lmonary arterial hypertension.

@nl

type

label

Overexpression of human bone m ...... lmonary arterial hypertension.

@ast

Overexpression of human bone m ...... lmonary arterial hypertension.

@en

Overexpression of human bone m ...... lmonary arterial hypertension.

@nl

prefLabel

Overexpression of human bone m ...... lmonary arterial hypertension.

@ast

Overexpression of human bone m ...... lmonary arterial hypertension.

@en

Overexpression of human bone m ...... lmonary arterial hypertension.

@nl

P1433

Q33265315-0E24A3B2-B286-4AD0-A2A2-EC727E479DAC

P1476

Q33265315-EC499651-15F6-43A7-91AC-78F1DED9F439

P2093

Q33265315-1294A694-E531-40B3-A18F-0E6CE7247F02

Q33265315-1AA08BEC-0042-4675-BCAE-1B6759ADD102

Q33265315-4EECE940-D7D4-40AC-AB00-F1FC7A8B9CFC

Q33265315-67CCD416-6255-4241-89B0-BEAFBA01C8DF

Q33265315-8417655C-547C-4032-B924-492BC6229620

Q33265315-9979CCF6-B741-4678-9B1A-2F2D85A682C7

P2860

Q33265315-0A95BD47-9400-41AF-828B-EE4E6194000A

Q33265315-103DEFC5-685E-4E8D-A90F-61F829A229AE

Q33265315-154E9BA7-F254-47EE-95EF-A0A8C18E9BAF

Q33265315-1AEB63D5-763B-41CC-8A03-516959F3EACE

Q33265315-216B3C87-B695-471D-AE13-2A8FF81A07F7

Q33265315-22AD87C2-0434-40BA-ABE7-B38E040C991A

Q33265315-2A8201A6-889B-455D-983A-1FB6B7E30913

Q33265315-3EA04656-D6C2-4A03-A257-7EC821D69591

Q33265315-4184FDA3-8C76-46EE-AF5A-6D7C10DB4668

Q33265315-4949C59E-DD8F-4000-970B-ED75A6F6714C

P304

Q33265315-82ACD143-5280-4675-9EA9-F138DE41918D

P31

Q33265315-B38F22B3-156D-47B2-B87F-8FE9724BAD64

P356

Q33265315-22C27308-CB79-4D55-9C1E-772F3928FE36

P433

Q33265315-4F99B96C-D27E-4AF3-8041-3BC8EF6F06A5

P478

Q33265315-B0638152-62D9-47F5-B2E1-A40352958B2E

P577

Q33265315-86A6EB25-0A33-494F-AE2E-65862628E81A

P5875

Q33265315-B1F1F707-F641-4FEF-B2C7-14EB16006172

P698

Q33265315-CBDC13B4-6377-4F2B-8EB2-FB4BA2C222B0

P921

Q33265315-0EF0C1E6-D6F6-41A0-A83F-870FA6C7924A

Q33265315-8B4D8B7D-4585-44B3-A9FE-94D7A8CFDEC7

Q33265315-DA9C03F8-6C0E-4651-A90E-87BC0316C841

P356

AJPLUNG.00309.2006

P1433

American Journal of Physiology - Lung Cellular and Molecular Physiology

P1476

Overexpression of human bone m ...... lmonary arterial hypertension.

@en

P2093

Evangelos D Michelakis

http://www.w3.org/2001/XMLSchema#string

Kyoko Hashimoto

http://www.w3.org/2001/XMLSchema#string

M Sean McMurtry

http://www.w3.org/2001/XMLSchema#string

Rohit Moudgil

http://www.w3.org/2001/XMLSchema#string

Sandra Bonnet

http://www.w3.org/2001/XMLSchema#string

Stephen L Archer

http://www.w3.org/2001/XMLSchema#string

P2860

Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

BMP type II receptor is required for gastrulation and early development of mouse embryos

Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels.

Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis.

Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

Pulmonary arterial hypertension in France: results from a national registry.

Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice

P304

L872-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPLUNG.00309.2006

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

292

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6657337

http://www.w3.org/2001/XMLSchema#string

P698

17142350

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension